358 related articles for article (PubMed ID: 26606329)
1. Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.
James ND; Spears MR; Clarke NW; Dearnaley DP; Mason MD; Parker CC; Ritchie AW; Russell JM; Schiavone F; Attard G; de Bono JS; Birtle A; Engeler DS; Elliott T; Matheson D; O'Sullivan J; Pudney D; Srihari N; Wallace J; Barber J; Syndikus I; Parmar MK; Sydes MR;
JAMA Oncol; 2016 Mar; 2(3):348-57. PubMed ID: 26606329
[TBL] [Abstract][Full Text] [Related]
2. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
James ND; Sydes MR; Clarke NW; Mason MD; Dearnaley DP; Spears MR; Ritchie AW; Parker CC; Russell JM; Attard G; de Bono J; Cross W; Jones RJ; Thalmann G; Amos C; Matheson D; Millman R; Alzouebi M; Beesley S; Birtle AJ; Brock S; Cathomas R; Chakraborti P; Chowdhury S; Cook A; Elliott T; Gale J; Gibbs S; Graham JD; Hetherington J; Hughes R; Laing R; McKinna F; McLaren DB; O'Sullivan JM; Parikh O; Peedell C; Protheroe A; Robinson AJ; Srihari N; Srinivasan R; Staffurth J; Sundar S; Tolan S; Tsang D; Wagstaff J; Parmar MK;
Lancet; 2016 Mar; 387(10024):1163-77. PubMed ID: 26719232
[TBL] [Abstract][Full Text] [Related]
3. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
James ND; Spears MR; Clarke NW; Dearnaley DP; De Bono JS; Gale J; Hetherington J; Hoskin PJ; Jones RJ; Laing R; Lester JF; McLaren D; Parker CC; Parmar MKB; Ritchie AWS; Russell JM; Strebel RT; Thalmann GN; Mason MD; Sydes MR
Eur Urol; 2015 Jun; 67(6):1028-1038. PubMed ID: 25301760
[TBL] [Abstract][Full Text] [Related]
4. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
5. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
James ND; de Bono JS; Spears MR; Clarke NW; Mason MD; Dearnaley DP; Ritchie AWS; Amos CL; Gilson C; Jones RJ; Matheson D; Millman R; Attard G; Chowdhury S; Cross WR; Gillessen S; Parker CC; Russell JM; Berthold DR; Brawley C; Adab F; Aung S; Birtle AJ; Bowen J; Brock S; Chakraborti P; Ferguson C; Gale J; Gray E; Hingorani M; Hoskin PJ; Lester JF; Malik ZI; McKinna F; McPhail N; Money-Kyrle J; O'Sullivan J; Parikh O; Protheroe A; Robinson A; Srihari NN; Thomas C; Wagstaff J; Wylie J; Zarkar A; Parmar MKB; Sydes MR;
N Engl J Med; 2017 Jul; 377(4):338-351. PubMed ID: 28578639
[TBL] [Abstract][Full Text] [Related]
6. Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Ali A; Hoyle A; Haran ÁM; Brawley CD; Cook A; Amos C; Calvert J; Douis H; Mason MD; Dearnaley D; Attard G; Gillessen S; Parmar MKB; Parker CC; Sydes MR; James ND; Clarke NW
JAMA Oncol; 2021 Apr; 7(4):555-563. PubMed ID: 33599706
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Parker CC; James ND; Brawley CD; Clarke NW; Hoyle AP; Ali A; Ritchie AWS; Attard G; Chowdhury S; Cross W; Dearnaley DP; Gillessen S; Gilson C; Jones RJ; Langley RE; Malik ZI; Mason MD; Matheson D; Millman R; Russell JM; Thalmann GN; Amos CL; Alonzi R; Bahl A; Birtle A; Din O; Douis H; Eswar C; Gale J; Gannon MR; Jonnada S; Khaksar S; Lester JF; O'Sullivan JM; Parikh OA; Pedley ID; Pudney DM; Sheehan DJ; Srihari NN; Tran ATH; Parmar MKB; Sydes MR;
Lancet; 2018 Dec; 392(10162):2353-2366. PubMed ID: 30355464
[TBL] [Abstract][Full Text] [Related]
8. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.
Dearnaley DP; Jovic G; Syndikus I; Khoo V; Cowan RA; Graham JD; Aird EG; Bottomley D; Huddart RA; Jose CC; Matthews JH; Millar JL; Murphy C; Russell JM; Scrase CD; Parmar MK; Sydes MR
Lancet Oncol; 2014 Apr; 15(4):464-73. PubMed ID: 24581940
[TBL] [Abstract][Full Text] [Related]
9. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.
James ND; Sydes MR; Mason MD; Clarke NW; Anderson J; Dearnaley DP; Dwyer J; Jovic G; Ritchie AW; Russell JM; Sanders K; Thalmann GN; Bertelli G; Birtle AJ; O'Sullivan JM; Protheroe A; Sheehan D; Srihari N; Parmar MK;
Lancet Oncol; 2012 May; 13(5):549-58. PubMed ID: 22452894
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.
Thompson IM; Tangen CM; Paradelo J; Lucia MS; Miller G; Troyer D; Messing E; Forman J; Chin J; Swanson G; Canby-Hagino E; Crawford ED
JAMA; 2006 Nov; 296(19):2329-35. PubMed ID: 17105795
[TBL] [Abstract][Full Text] [Related]
11. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
Sydes MR; Spears MR; Mason MD; Clarke NW; Dearnaley DP; de Bono JS; Attard G; Chowdhury S; Cross W; Gillessen S; Malik ZI; Jones R; Parker CC; Ritchie AWS; Russell JM; Millman R; Matheson D; Amos C; Gilson C; Birtle A; Brock S; Capaldi L; Chakraborti P; Choudhury A; Evans L; Ford D; Gale J; Gibbs S; Gilbert DC; Hughes R; McLaren D; Lester JF; Nikapota A; O'Sullivan J; Parikh O; Peedell C; Protheroe A; Rudman SM; Shaffer R; Sheehan D; Simms M; Srihari N; Strebel R; Sundar S; Tolan S; Tsang D; Varughese M; Wagstaff J; Parmar MKB; James ND;
Ann Oncol; 2018 May; 29(5):1235-1248. PubMed ID: 29529169
[TBL] [Abstract][Full Text] [Related]
12. Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience.
Murgic J; Jaksic B; Prpic M; Kust D; Bahl A; Budanec M; Prgomet Secan A; Franco P; Kruljac I; Spajic B; Babic N; Kruslin B; Zovak M; Zubizarreta E; Rosenblatt E; Fröbe A
Radiat Oncol; 2021 May; 16(1):88. PubMed ID: 33980277
[TBL] [Abstract][Full Text] [Related]
13. Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.
Mason MD; Clarke NW; James ND; Dearnaley DP; Spears MR; Ritchie AWS; Attard G; Cross W; Jones RJ; Parker CC; Russell JM; Thalmann GN; Schiavone F; Cassoly E; Matheson D; Millman R; Rentsch CA; Barber J; Gilson C; Ibrahim A; Logue J; Lydon A; Nikapota AD; O'Sullivan JM; Porfiri E; Protheroe A; Srihari NN; Tsang D; Wagstaff J; Wallace J; Walmsley C; Parmar MKB; Sydes MR;
J Clin Oncol; 2017 May; 35(14):1530-1541. PubMed ID: 28300506
[TBL] [Abstract][Full Text] [Related]
14. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
Parker CC; James ND; Brawley CD; Clarke NW; Ali A; Amos CL; Attard G; Chowdhury S; Cook A; Cross W; Dearnaley DP; Douis H; Gilbert DC; Gilson C; Gillessen S; Hoyle A; Jones RJ; Langley RE; Malik ZI; Mason MD; Matheson D; Millman R; Rauchenberger M; Rush H; Russell JM; Sweeney H; Bahl A; Birtle A; Capaldi L; Din O; Ford D; Gale J; Henry A; Hoskin P; Kagzi M; Lydon A; O'Sullivan JM; Paisey SA; Parikh O; Pudney D; Ramani V; Robson P; Srihari NN; Tanguay J; Parmar MKB; Sydes MR;
PLoS Med; 2022 Jun; 19(6):e1003998. PubMed ID: 35671327
[TBL] [Abstract][Full Text] [Related]
16. The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1|RT Comparison".
Ali A; Hoyle AP; Parker CC; Brawley CD; Cook A; Amos C; Calvert J; Douis H; Mason MD; Attard G; Parmar MKB; Sydes MR; James ND; Clarke NW;
Eur Urol Oncol; 2020 Aug; 3(4):412-419. PubMed ID: 32591246
[TBL] [Abstract][Full Text] [Related]
17. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
18. High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial.
Zapatero A; Guerrero A; Maldonado X; Álvarez A; San-Segundo CG; Rodríguez MÁC; Solé JM; Olivé AP; Casas F; Boladeras A; de Vidales CM; de la Torre MLV; Vara S; Sanz JL; Calvo FA
Lancet Oncol; 2022 May; 23(5):671-681. PubMed ID: 35427469
[TBL] [Abstract][Full Text] [Related]
19. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.
Bolla M; Van Tienhoven G; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Billiet I; Torecilla JL; Pfeffer R; Cutajar CL; Van der Kwast T; Collette L
Lancet Oncol; 2010 Nov; 11(11):1066-73. PubMed ID: 20933466
[TBL] [Abstract][Full Text] [Related]
20. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.
Michalski JM; Moughan J; Purdy J; Bosch W; Bruner DW; Bahary JP; Lau H; Duclos M; Parliament M; Morton G; Hamstra D; Seider M; Lock MI; Patel M; Gay H; Vigneault E; Winter K; Sandler H
JAMA Oncol; 2018 Jun; 4(6):e180039. PubMed ID: 29543933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]